Duavee vs Bijuva: The 9 Differences That Actually Decide It

Both are approved for hot flashes. Only Duavee is also approved to help prevent osteoporosis. No trial has ever compared the two head to head.

What changes the answer

• Progestogens have caused you problems before. Duavee is the only FDA-approved product that pairs systemic estrogen with a SERM instead of a progestogen.
• Bone density is part of why you're here. Only Duavee carries an approved indication for preventing postmenopausal osteoporosis.
• You have kidney impairment, or you're over 75. Duavee's label says use is not recommendedin these groups, because they weren't studied.
• You're paying cash. Duavee is listed on the federal TrumpRx platform at $30.30 for 30 tablets.
• You're on Medicare Part D.Bijuva has a separate Part D coupon program with its own strict rules. Duavee doesn't.
• Unpredictable bleeding would be a dealbreaker. The two drugs looked very different against their own placebo groups.

Best for / not for you

What we actually verified

Between 27 and 28 July 2026, we opened and read:

• Duavee's FDA prescribing information on DailyMed — Wyeth Pharmaceuticals (Pfizer), set ID e1b75458-2e5b-46b9-92c6-fa6daba3770f
• Bijuva's FDA prescribing information on DailyMed — Mayne Pharma, set ID bc52489a-5149-411d-9665-2c75405ad15d, version 13
• The FDA's page listing menopause hormone products with updated prescribing information
• The published 2026 Express Scripts National Preferred Formulary — the drug list and both exclusion documents
• TrumpRx.gov's Duavee page
• Five cash-price sources: GoodRx, SingleCare, SaveHealth, Drugs.com, and Rx.com
• Both manufacturers' published savings terms
• The FDA National Drug Code directory and generic-approval records
• Patient review databases — for language and common complaints only, never as medical evidence

What we did not do:run a head-to-head trial (none was identified), take either medication, survey pharmacies for stock, or confirm coverage under any individual plan. Where a number couldn't be traced to a current primary source, we left it out and said so.

The 9 differences at a glance

Duavee is conjugated estrogens 0.45 mg plus bazedoxifene 20 mg, taken as one tablet daily. It was FDA-approved in 2013 for moderate-to-severe hot flashes and for preventing postmenopausal osteoporosis. Bijuva is estradiol plus micronized progesterone in a capsule taken each evening with food, FDA-approved in 2018 for moderate-to-severe hot flashes only. Both are labeled for postmenopausal women who still have a uterus.

Follow-up questions — is Duavee discontinued, what about hysterectomy, what about vaginal symptoms, can you switch, and what to ask your clinician — are answered further down.

1. How each one protects your uterus

Duavee combines conjugated estrogens with bazedoxifene, a selective estrogen receptor modulator (SERM). Bijuva combines estradiol with micronized progesterone, a progestogen. Both are systemic treatments for postmenopausal women with a uterus, but they manage estrogen's effect on the uterine lining using different components.

Here's the problem both drugs are solving.

Estrogen is what calms hot flashes. Estrogen also thickens the lining of the uterus. Left unopposed, that thickening raises the risk of endometrial hyperplasia — overgrowth of the lining that can become cancer over time. So systemic estrogen given to a woman who still has her uterus has to come with something that counters that effect.

For decades, that “something” meant a progestogen — either progesterone itself or a synthetic version called a progestin. That's Bijuva's design, and it's the design behind nearly every combination hormone pill sold in the US.

Duavee does it differently. Instead of a progestogen, it pairs conjugated estrogens with bazedoxifene. Per Duavee's label, the bazedoxifene component reduces the risk of endometrial hyperplasia that comes with the conjugated-estrogen component. Researchers call this pairing a tissue-selective estrogen complex, or TSEC. Duavee is the only one on the US market.

And here is the sentence on Duavee's label that changes everything downstream:

Read it twice. Duavee doesn't just leave the progestogen out. It instructs against adding one.That makes it the only FDA-approved product in the US that pairs systemic estrogen with a SERM rather than a progestogen — which matters enormously if a progestogen is the thing that made you feel terrible.

Whether that makes Duavee the right choice for you depends on whythe progestogen was stopped and on the rest of your history. But it's the reason this comparison isn't a coin flip.

This single design difference drives most of what follows: the bleeding evidence, the side-effect profiles, the dosing rules, and which women each drug rules out.

Two things to get right about the words

Duavee isn't “estrogen-only.”It has two active ingredients. People call it estrogen-only because there's no progesterone in it. That's not the same thing.

Bazedoxifene isn't a progesterone substitute. It isn't a hormone. It's a SERM with tissue-selective effects. If someone told you Duavee contains “a synthetic progesterone,” that's wrong.

Is “bioidentical” the tiebreaker?

Many women arrive here assuming Bijuva wins automatically because it's bioidentical — chemically identical to the hormones the body makes.

Bijuva's own manufacturer settles that on its website: there are no data suggesting bioidentical hormones are superior to synthetic hormones. That's the manufacturer, on its own marketing page.

The fuller picture: observational research — not randomized trials, and not studies of Duavee versus Bijuva — has associated micronized progesterone with a lower breast-cancer signal than synthetic progestogens as a class. The same body of work raises questions about long-term endometrial protection. Because the randomized evidence doesn't exist, a trial is currently recruiting to compare oral micronized progesterone against norethisterone acetate when each is combined with oral estrogen. It is not a Duavee-versus-Bijuva trial.

So “bioidentical” is an open question that cuts both ways, not a settled advantage.

2. What each one is approved to treat

Both Duavee and Bijuva are FDA-approved to treat moderate-to-severe vasomotor symptoms — hot flashes and night sweats — in postmenopausal women with a uterus. Duavee carries a second approved use: prevention of postmenopausal osteoporosis. Bijuva does not. Neither drug is approved to treat vulvar and vaginal atrophy.

That second indication is real, not marketing. In Duavee's studies, women taking it showed increases in lumbar-spine bone mineral density compared with placebo over 24 months. That evidence is why the indication exists.

But Duavee's label draws two hard lines around it:

• The indication is prevention, not treatment. Duavee is not FDA-approved to treat established osteoporosis.
• When Duavee is being considered only for bone prevention, the label says it should be used only in women at significant risk of postmenopausal osteoporosis, and that non-estrogen medications should be carefully considered first.

So “Duavee helps bones” is accurate. “Duavee is a bone drug” isn't. If bone prevention is the only goal, that label limitation is the conversation to have.

What neither one does

Neither drug is indicated for vaginal dryness, burning, or pain with sex. We're being blunt because at least one widely visible “medically reviewed” drug page currently states that Duavee treats vaginal dryness. Its label doesn't support that.

If vaginal symptoms are your main problem, skip to that section — and read it before you assume you can simply add a vaginal estrogen on top.

3. Which works better for hot flashes?

Both drugs reduced moderate-to-severe hot flashes compared with placebo in their own clinical trials. No direct Duavee-versus-Bijuva trial was identified in either current label or in searches completed on 28 July 2026. The two programs also measured symptoms on different scales — Duavee's per day, Bijuva's per week — so their numbers cannot be converted into a head-to-head ranking.

Duavee.In a 12-week study of 127 women on Duavee and 63 on placebo, starting from about 10.3 hot flashes a day, the adjusted mean change at week 12 was −7.6 on Duavee versus −4.9 on placebo. The adjusted between-group difference was −2.7 hot flashes per day (95% CI −3.8 to −1.6), p<0.001.

Bijuva.In its pivotal trial, mean weekly hot-flash frequency changed by −53.7 on the 0.5 mg/100 mg strength and −55.1 on the 1 mg/100 mg strength at week 12, versus −40.2 on placebo.

Why you can't rank these

Both labels caution that results observed in one drug's clinical trials cannot be directly compared with rates from another drug's trials. What you can conclude: each drug outperformed its own placebo. What you cannot conclude: that either works better than the other.

That's genuinely useful, by the way. It means efficacy shouldn't be your tiebreaker — the fit differences below should be.

4. How many strengths does each come in?

Bijuva comes in two strengths: 0.5 mg estradiol with 100 mg progesterone, and 1 mg estradiol with 100 mg progesterone. Its label generally directs starting at the lower strength and adjusting based on clinical response. Duavee comes in one fixed strength — conjugated estrogens 0.45 mg with bazedoxifene 20 mg.

This matters more than it looks. If Bijuva isn't enough, your prescriber has somewhere to go. With Duavee, there's one dose — if it doesn't fit, the next move isn't a dose change, it's a different medication.

That said, a second strength doesn't guarantee you'll land on the right level. It just means the conversation has one more option in it.

5. How you take it, day to day

Duavee is one tablet daily at a consistent time, with or without food, swallowed whole — and it must stay in its original foil packaging rather than a pill organizer. Bijuva is one capsule taken each evening with food, and the food requirement is a dosing instruction rather than a preference, because food substantially changes how much progesterone is absorbed.

This is the section that quietly decides whether a woman stays on her medication.

Bijuva's food rule is real pharmacology

Taking Bijuva with a meal changes absorption in ways the label documents:

• Total estradiol exposure doesn't change. But peak estradiol concentration drops by about half, and the time to that peak shifts from roughly 1 hour to about 12.
• Progesterone exposure rises sharply— peak concentration up 162%, total exposure up 79%.

Taking Bijuva without food produces materially different progesterone exposure from the fed conditions described in the label. If your dinner time is unpredictable, or you often skip it, say so at your appointment.

Duavee's packaging rule came out of a recall

Duavee's label is unusually specific:

• Dispense and keep in the original package
• Don't remove a tablet until immediately before use
• Do not place Duavee in pill boxes or pill organizers
• Open one foil pouch at a time
• Write down the date you open a pouch
• Do not use a pouch that's been open more than 60 days

Pfizer issued a global voluntary recall in May 2020 to implement packaging updates ensuring the product stayed stable through its shelf life, and announced Duavee back in stock in the US on 5 June 2023 with improved packaging. The rules on your label today came out of that.

A practical note on Duavee's 60-day rule: a 90-day fill still works, because you open one pouch at a time. But the 60-day clock starts when a pouch is opened, which limits stockpiling.

6. Which one is more likely to make you bleed?

In Duavee's two studies, 83% and 88% of women met the cumulative-amenorrhea endpoint — no bleeding or spotting during the first year — compared with 85% and 84% in the matching placebo groups. In Bijuva's 52-week study, 67.6% of women on the lower strength and 56.1% on the higher strength met that endpoint, compared with 78.9% on placebo. These come from separate trials and cannot establish that one drug causes less bleeding than the other.

Let's slow down, because this is the number most women want and almost nobody shows side by side.

The measure is cumulative amenorrhea— the proportion of women with no bleeding or spotting across the study period.

In each Duavee study, the proportion meeting that endpoint was descriptively similar to its own placebo group. 83% versus 85%. 88% versus 84%.

In Bijuva's study, a smaller proportion met the endpoint than in its own placebo group. 67.6% and 56.1% versus 78.9%.

Here's why we frame it that way instead of putting the two drugs head to head: comparing each drug against its own placebo arm is the only comparison the data supports. The trials enrolled different women, ran different lengths, and used different definitions. You cannot subtract 67.6 from 83 and call the difference an effect of the drug.

What you cansay: Duavee's cumulative-amenorrhea percentages were close to its own placebo percentages, and Bijuva's were lower than its placebo percentage. That pattern does not establish that Duavee causes less bleeding than Bijuva. It's a legitimate question to raise with your prescriber. It is not a prediction about you.

What about the uterine lining itself?

Both drugs were checked with biopsies. Endometrial hyperplasia was uncommon in each product's own program:

Endometrial hyperplasia was uncommon in each product's own clinical program. The separate trials do not establish comparative endometrial safety — the denominators, biopsy schedules, populations, and durations all differ.

7. Side effects — and the weight question

Duavee's most common label-reported side effects were muscle spasms (9% vs 6% on placebo), nausea (8% vs 5%), diarrhea (8% vs 5%), and indigestion (7% vs 6%). Bijuva's most commonly reported reactions were breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge, and pelvic pain. Because these percentages come from separate trials with different reporting thresholds, they cannot establish that one drug is better tolerated than the other.

Duavee's reported side effects (≥5%, n=1,224 vs 1,069 placebo)

One number worth noticing: 7.5% of women stopped Duavee because of an adverse reaction, versus 10.0% on placebo. More women left the placebo arm than the drug arm. That single comparison does not establish that Duavee is better tolerated overall, or better tolerated than Bijuva — but it's a useful counterweight if you've been reading side-effect lists with rising dread.

Bijuva's reported side effects

Breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge, and pelvic pain.

Does either one cause weight gain?

This is one of the most-searched questions about both drugs. The honest answer:

Neither label provides a reliable weight-gain rate, and no head-to-head data exist.

Bijuva's post-marketing section includes reports of increased weight and fluid retention. But the label itself notes that because these reports come voluntarily from a population of uncertain size, their frequency and their causal relationship to the drug cannot be reliably established. Weight gain does not appear among the common reactions in Duavee's trial tables. That is not the same as “Duavee doesn't cause weight gain.” Absence from a trial table isn't proof of absence.

What women actually report

For context only. These are small, self-selected samples anyone can post to, and they are not evidence of how well or how safely either drug works:

• Drugs.com: Bijuva averages 6.1 out of 10 from 55 ratings. Duavee averages 6.4 out of 10 from 35 ratings.
• Duavee's hot-flash reviews average 7.5 from 15 ratings, while its broader “postmenopausal symptoms” reviews average 5.9 from 14. Same drug, different scores depending on what women were taking it for.

Three real comments, because the friction is more useful than the praise:

These are individual, unverified accounts describing personal experience only. They are not evidence of effectiveness, safety, availability, or typical results.

8. Why one label has a black-box warning and the other doesn't

The two current labels have different revision dates and different warning status. On 12 February 2026, the FDA approved the removal of cardiovascular, breast-cancer, and probable-dementia language from the boxed warnings of six menopause hormone therapy products. Bijuva was one of the six, and its current prescribing information carries no boxed warning. Duavee's prescribing information is still stamped “Revised: 3/2024” and its boxed warning remains. The FDA has not published a product-specific explanation for Duavee's timing.

What the FDA did

In November 2025, following an expert panel that July, the FDA asked manufacturers of menopause hormone therapy products to change their labels after reviewing the scientific literature. The agency requested removal of cardiovascular-disease, breast-cancer, and probable-dementia statements from the boxed warning, and removal of the “lowest effective dose for the shortest duration” instruction from the box. It did not request removal of cardiovascular and breast-cancer information from the Warnings and Precautions sections. The risk information moved. It didn't disappear.

29 companies submitted proposed labeling changes. On 12 February 2026, the FDA approved the first six: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. Duavee wasn't among them.

The mismatch you'll actually run into

Four things this does not mean

1. Removing a warning does not remove risk.The underlying Women's Health Initiative data is still in Bijuva's Warnings and Precautions section.
2. Duavee's boxed warning is not a 2026 finding about Duavee. It reflects a label last revised in March 2024, before the FDA's review concluded.
3. You cannot rank two drugs' safety by the dates on their paperwork.
4. Duavee's absence from the FDA's list does not establish whether or when a Duavee label change will happen.

Take this to your appointment

Before we go further — the honest version

In the dated cash prices we checked, both brands cost several times what generic oral hormone regimens cost.

Separate generic oral estradiol runs roughly $10–$30 a month and generic micronized progesterone roughly $15, against Bijuva at roughly $241–$306 retail. Generic estradiol with norethindrone acetate — a one-pill combination — runs around $21 against Bijuva's retail price. And that generic combination is the exact alternative Express Scripts names when it excludes Bijuva from its formulary.

If cost is your only variable, neither brand is the rational buy.

Now here's what they actually buy you.

Bijuva buys simplicity. One capsule instead of two prescriptions, two refill cycles, and potentially two copays. That sounds trivial in month one. Ask someone in month eleven.

Duavee buys something no generic on the US market offers.It's the only approved product pairing systemic estrogen with a SERM instead of a progestogen — with cumulative-amenorrhea percentages that tracked its own placebo group, and an approved indication for preventing bone loss. There is no generic version of that combination. Not one.

For a woman whose actual problem is the progestogen — who tried progesterone and felt awful, tried a synthetic progestin and felt worse — the cheap drug is not the same drug.

And if that's not you?If progestogens have never bothered you, bone density isn't on your radar, and money is the binding constraint — you probably shouldn't be choosing between these two at all. We'd rather tell you that than talk you into a $269 capsule.

→ See the generic routes and what everything costs

9. What they cost in 2026

As of 28 July 2026, Duavee's published cash prices ranged from about $191 to $267 for 30 tablets, with a listed price of $30.30 through the federal TrumpRx platform. Bijuva's ranged from about $241 to $306 for 30 capsules depending on strength and source. Manufacturer savings cards for both require commercial insurance. Prices vary by pharmacy, ZIP code, strength, and stock, so treat every figure here as a dated snapshot.

The TrumpRx route — real, and worth understanding

Duavee's TrumpRx page lists it at $30.30for 30 tablets of 0.45/20 mg, against a reference price of $202.00 — an 85% discount. The coupon routing is printed on the page (BIN 015995, PCN GDC, Group MAHA, Member ID TRUMPRX).

You may also see $30.30 quoted on GoodRx. That isn't independent confirmation.GoodRx is a TrumpRx launch partner — it's the same Pfizer-supported cash price visible in two places, not two separate deals.

The savings cards — and the arithmetic nobody shows you

Duaveesits on a Pfizer menopause savings card advertised as “pay as little as $25,” with savings of up to $110 per 30-day fill. Commercial insurance only; state and federal beneficiaries and cash-paying patients are not eligible.

Here's the arithmetic: with a $110 per-fill ceiling, “$25” is only reachable if your copay is $135 or less. A $200 copay becomes $90, not $25. And the card requires coverage for that drug— if your plan denies it, the card does nothing.

Bijuva has a separate Mayne Pharma savings program for commercially insured patients, with variable out-of-pocket amounts.

The Medicare route most Part D readers never find

Bijuva offers a Medicare Part D Alternative Coupon Program, which may apply when a Part D plan does not cover Bijuva, or when the patient's plan cost exceeds $50 for a 30-count supply. The terms are strict, and you need all of them:

• You buy Bijuva outside your Part D benefit
• You notify your plan
• You do not seek reimbursement
• The purchase does not count toward your Part D true out-of-pocket spending

Duavee does not offer an equivalent Part D program. If you're on Medicare Part D and your plan won't cover Bijuva, this is the route worth asking your pharmacist about — and it's the one place on this page where Bijuva has a clear structural advantage over Duavee.

10. Which one is your plan more likely to cover?

Coverage depends on your specific plan, but on one widely used published template the answer runs opposite to what most women expect. On the 2026 Express Scripts National Preferred Formulary, Duavee appears on the drug list while Bijuva appears on the exclusion list — on both the standard and Flex versions — with generic estradiol/norethindrone acetate named as the preferred alternative. A formulary listing is not a guarantee of coverage, and individual plans can modify it.

On 28 July 2026, we opened the published 2026 Express Scripts documents and read both sides.

Duavee appears on the drug list.We found it in the “D” section, between DROXIA and DULERA. Document code COMP1702A-26, effective 1 January through 31 December 2026.

Bijuva appears on the exclusion list.It sits in the row labeled “Estrogen/Progestin Combinations (Oral),” alongside Premphase and Prempro. The preferred alternatives named in its place are estradiol/norethindrone acetate and ethinyl estradiol/norethindrone acetate— both generics. Bijuva is excluded on the standard National Preferred Formulary and on the Flex version (document EXCL-FLEX-26, effective 1 January 2026).

How to check your own plan in five minutes

1. Find your pharmacy benefit manager.It's on your insurance card — Express Scripts, CVS Caremark, Optum Rx, or another.
2. Search your plan's 2026 drug list for both brand names. Note the tier, and any PA, ST, or QL flag.
3. If a claim gets rejected, ask the pharmacy which NDC was submitted.Both drugs have more than one National Drug Code. It's a reasonable troubleshooting step.

If your plan says no

You have a path. On the standard Express Scripts formulary, a prescriber can request a coverage review when there's a clinical reason to continue a non-covered medication. Your plan controls the criteria, the forms, the appeal rights, and who may submit the request.

But read this part if you've had a bad time with progestogens: the preferred alternative named on that exclusion row is a progestogen combination. If a progestogen caused you a documented problem, that's not a loophole — that's precisely the kind of clinical reason a coverage review exists to consider. Make sure it's in your chart before the request goes in.

Is Duavee discontinued?

Current official sources do not show Duavee as discontinued. As of our check on 28 July 2026, the FDA's National Drug Code record (NDC 0008-1123, Wyeth Pharmaceuticals) shows no marketing end date and a current package status, Pfizer previously announced the product's return to the US market in June 2023, the DailyMed record remains active, and TrumpRx lists it with an active price. Some discount websites state Duavee was discontinued for business reasons.

We're giving this its own section because the claim is costing women a medication they were doing well on.

Where the confusion comes from

1. The 2020 recall was real— a global voluntary recall to update packaging and ensure stability through shelf life, not a safety finding about the medicine. Pfizer announced the product back in stock in the US on 5 June 2023.
2. Intermittent back-orders were real in the years around that. Patient reviews from that period reference them directly.
3. At least one discount site still says “discontinued due to business reasons” while selling coupons for the drug on the same page.

The pharmacy call script

Call before you drive over. Ask for the pharmacist.

If you're being told a medication you've done well on is gone, get that confirmed before you switch. Switching something you tolerate is not a small thing.

Would the generic route be better?

Separate generic oral estradiol and generic micronized progesterone contain the same hormone types as Bijuva at a fraction of the price, but they are separate products — not the FDA-rated generic version of the fixed-dose Bijuva capsule. There is no generic equivalent to Duavee: no generic product on the US market pairs systemic estrogen with a SERM instead of a progestogen.

If you're comparing against Bijuva

Two legitimate, widely used routes:

• Separate components:generic oral estradiol (roughly $10–$30 a month) plus generic micronized progesterone (around $15 a month)
• A one-pill generic combination:generic estradiol/norethindrone acetate, around $21 — the same alternative Express Scripts names when it excludes Bijuva

What you give up: two prescriptions instead of one, two refill cycles, potentially two copays, and one more way to miss a dose. Note also that the one-pill generic uses norethindrone acetate, a synthetic progestin, not micronized progesterone. They are different progestogens and are not interchangeable dose for dose.

If you're comparing against Duavee

There is no generic route.Duavee is the only conjugated estrogens plus bazedoxifene product in the United States. If your reason for wanting it is that you can't take a progestogen, no generic substitution exists.

The generic status of both is genuinely strange

Bijuva has an FDA-approved generic.Amneal received approval for estradiol/progesterone 1 mg/100 mg — ANDA 214293 — on 16 May 2022.

It is not currently marketed. The publicly disclosed patent settlement permits commercialization beginning in May 2032, subject to specified earlier-entry circumstances, and the last patent listed for Bijuva runs into late 2032. FDA approval does not mean immediate market availability.

Duavee has no FDA-approved generic. Patent-expiry estimates from third-party trackers are not approval or launch dates.

Who shouldn't take either one

Both Duavee and Bijuva share a substantial list of contraindications, including undiagnosed abnormal genital bleeding, known or past breast cancer, active or past blood clots, and known hepatic impairment or disease. Duavee's contraindications also include pregnancy, and its label says use is not recommended in renal impairment or in women over 75. Bijuva is not indicated for use in pregnancy.

Contraindicated for both

• Undiagnosed abnormal genital bleeding
• Known, suspected, or past breast cancer
• Known or suspected estrogen-dependent cancer
• Active or past venous thromboembolism — DVT or pulmonary embolism
• Active or past arterial thromboembolic disease — stroke or heart attack
• Known hepatic impairment or disease
• Known anaphylactic reaction, angioedema, or hypersensitivity to the product
• Inherited clotting disorders — protein C, protein S, or antithrombin deficiency

Duavee additionally lists pregnancy as a contraindication. Bijuva is not indicated for use in pregnancy.

Duavee-specific cautions

Renal impairment.Duavee's label says use is not recommended.

Age over 75.Not recommended — because Duavee was never studied in women over 75. Not “found risky.” Never studied.

Bijuva-specific caution

Bijuva's label reports that after adjusting for body mass index, smoking, alcohol use, and baseline estradiol, the drug did not demonstrate statistically significant reductions in both frequency and severity of hot flashes by week 12 in women who self-identified as Black or African American — 31% of the trial population.

Read that carefully. This is an adjusted subgroup finding in a study that was not designed or powered to establish a definitive race-specific treatment effect. It is not evidence that Bijuva doesn't work for Black women, and it must not be used to rank Bijuva against Duavee. It is a reason to raise the question and agree on a clear check-in point rather than waiting six months.

What both labels agree on

Both state that serum FSH and estradiol levels have not been shown to be useful in managing moderate-to-severe vasomotor symptoms.

If you've been told your hormone levels are “normal” so you don't need treatment, that sentence is printed in both labels. Bring it.

Both labels also direct monitoring of thyroid functionin women receiving thyroid replacement therapy. Flag it if that's you.

When online care isn't the right starting point

• Bleeding after menopause that hasn't been evaluated
• A new breast lump or nipple change
• A complicated personal or family clotting history
• Significant liver disease
• A recent cardiac or neurological event
• Uncertainty about what was removed in a past surgery
• Symptoms that may not be menopause at all

What if I don't have a uterus?

Both Duavee and Bijuva are labeled for postmenopausal women who still have a uterus. Each contains a second component — bazedoxifene in Duavee, progesterone in Bijuva — that addresses estrogen's effect on the uterine lining. After a hysterectomy, that component generally isn't needed, and estrogen alone is usually the more direct treatment discussion.

If your uterus has been removed, you're likely comparing the wrong two products.

One thing to be clear about:a hysterectomy changes the need for endometrial protection. It does not make either product risk-free or automatically appropriate — the cardiovascular, clotting, breast, gallbladder, liver, and hypersensitivity considerations in both labels still apply.

Questions worth asking instead:

• Do I need a combination product at all, or is estrogen alone appropriate?
• Which route — pill, patch, gel, or spray — fits my history best?
• Were my ovaries or cervix left in place, and does that change anything?
• Does the reason for my hysterectomy affect the decision?

One note that's easy to misread: during the February 2026 changes, the FDA requested that endometrial-cancer boxed-warning language be retained for systemic estrogen-alone products. That's about the product category, not about you specifically. Your prescriber will explain how it applies.

What if vaginal dryness is my main symptom?

Neither Duavee nor Bijuva is FDA-approved to treat vulvar and vaginal atrophy — the dryness, burning, and pain with sex many women experience after menopause. Both are systemic oral therapies approved for hot flashes. When vaginal symptoms are the main or only problem, a local vaginal treatment is typically the more targeted discussion.

If you're taking Bijuvaand vaginal symptoms persist, any local add-on is still an individualized prescribing decision. Ask; don't assume.

If vaginal symptoms are your only problem:a local product delivers estrogen where you need it with much lower systemic exposure. That's a different conversation, and it may not need either drug on this page.

→ Our guide to vaginal estrogen options

Can you switch between them?

Switching between Duavee and Bijuva is a prescriber decision, and there is no dose conversion between them because they don't contain comparable ingredients. Moving from Duavee to Bijuva means adding a progestogen. Moving from Bijuva to Duavee means removing one, and Duavee's label directs that no progestin be taken alongside it.

What changes in each direction

Duavee → Bijuva.You're introducing micronized progesterone — a new ingredient with its own effects, risks, and tolerability considerations. You're also moving to a product without an osteoporosis-prevention indication.

Bijuva → Duavee.You're removing the progestogen and moving to a SERM-based product whose label instructs against taking progestins or additional estrogens with it.

What this page will not tell you

• No dose conversion ratio. There isn't one — the ingredients aren't comparable.
• No taper, overlap, or washout schedule. The prescriber has to decide the transition, precisely because Duavee's label prohibits concurrent progestins and additional estrogens.
• No cross-trial side-effect scoreboard.

What to bring if you're switching

1. What you're taking now, and how long you've been on it
2. Exactly what's wrong — bleeding, mood, weight, breast tenderness, or symptoms that never improved
3. Whether you've tried other progestogens, and what happened
4. Your plan's coverage for both, and any prior-authorization requirement
5. What “better” would look like, so you both know what you're aiming at

The 12 questions to bring to your appointment

Print this. It's the most useful thing on this page.

1. Do I need systemic hormone therapy, or are my symptoms mainly local?
2. Does my uterus or surgical history change what's available to me?
3. Why are you suggesting estrogen plus bazedoxifene, or estrogen plus progesterone, for me specifically?
4. Have progestogens caused me a documented problem before — and is that in my chart?
5. Is bone loss part of what we're treating?
6. Is an oral product right for me given my history, or should we look at a patch or gel?
7. If Bijuva, which strength are we starting with and why?
8. How will we monitor bleeding, and what would count as a problem?
9. What side effect should make me call you rather than wait?
10. When do we reassess, and what does “working” look like?
11. What will this cost under my plan, and does it need prior authorization?
12. If the pharmacy can't get it, what's plan B?

What providers say, and what we verified

Because some links on this page earn us a commission, here's the same claim ledger we'd want to see:

Providers we deliberately left out, and why: Winona and Inner Balance lead with compounded formulations. This page is about two FDA-approved brand-name products, and compounded preparations are not FDA-approved and are not interchangeable with either one.

How we compared Duavee and Bijuva

This comparison follows The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule. We assign no numeric scores, because the right answer depends on your treatment goals and medical history rather than on a ranking we could invent.

We evaluate on five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. For a comparison of two medications rather than two providers, medication fit carries most of the weight.

Our source hierarchy

1. FDA prescribing information, as published on DailyMed
2. FDA safety communications and labeling actions
3. Clinical study tables within those labels
4. The Menopause Society, ACOG, and peer-reviewed literature
5. Official manufacturer pages, for commercial terms only
6. Dated pharmacy price sources
7. Patient reviews — for language and common complaints only, never as medical evidence

What we could not verify

• No head-to-head trial was identified in either current label or in searches completed 28 July 2026.
• We did not complete a datable direct search for Bijuva on TrumpRx, so we make no claim about its presence or absence there.
• We did not survey pharmacies, so we make no claim about how often either drug is in stock.
• We did not verify that any specific telehealth provider prescribes either drug.
• We cannot confirm coverage under your plan. The Express Scripts National Preferred Formulary is one published template; plans modify it.
• We could not confirm whether California and Massachusetts coupon restrictions apply to Duavee's TrumpRx coupon.
• We have not taken either medication.

How this page stays current

Duavee's label status and both drugs' cash prices are re-checked monthly. The formulary findings are re-checked when the 2027 documents publish and spot-checked quarterly. Both manufacturer programs are re-verified before the end of 2026. The “Last verified” date at the top changes only when the checks are actually redone — not when we edit a sentence.

Found something we got wrong? Tell us. We publish corrections at /corrections/.

Our relationships

We earn nothing on Duavee or Bijuva. Some provider links on this page are paid links, and each one is labeled where it appears. Those relationships don't affect the tables — every figure traces to a dated document you can open yourself. Full disclosure.

Duavee vs Bijuva: frequently asked questions

Sources. Duavee prescribing information, DailyMed set ID e1b75458-2e5b-46b9-92c6-fa6daba3770f(Wyeth Pharmaceuticals, a subsidiary of Pfizer), checked 28 July 2026 · Bijuva prescribing information, DailyMed set ID bc52489a-5149-411d-9665-2c75405ad15d(Mayne Pharma), version 13, checked 28 July 2026 · FDA, “Menopausal Hormone Therapies with Updated Prescribing Information,” checked 28 July 2026 · FDA press announcement, 12 February 2026 · FDA labeling-change request, November 2025 · 2026 Express Scripts National Preferred Formulary drug list (COMP1702A-26) and exclusion documents, including the Flex exclusions (EXCL-FLEX-26), effective 1 January–31 December 2026 · TrumpRx.gov Duavee page · FDA National Drug Code Directory (NDC 0008-1123) · FDA 2022 First Generic Drug Approvals (ANDA 214293) · Pfizer press release, 5 June 2023 · Pfizer menopause savings card and Pfizer RxPathways published terms · Mayne Pharma savings program and Medicare Part D Alternative Coupon Program published terms · GoodRx, SingleCare, SaveHealth, Drugs.com price guide, Rx.com — all checked 28 July 2026 · Drugs.com and WebMD review databases, retrieved July 2026.

The HRT Index is the independent decision resource for online menopause and HRT care. Educational content only — not medical advice. Always talk to a qualified clinician about your own situation.